Latest News
Climb Bio, Inc.
- Form 8K Climb Bio Inc For: 23 October By Investing.com
- Climb Bio reports Phase 1 data for IgAN drug candidate By Investing.com
- Climb Bio unveils additional Phase 1 results for CLYM116 with Mabworks partnership in IgAN
- Climb Bio, Inc. Estimates – BOATS:CLYM
- Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
- Why is Climb Bio stock surging today?
- Climb Bio stock initiated at buy by Deutsche Bank on autoimmune pipeline
- Climb Bio's Upcoming Data Updates on CLYM116, Budoprutug to Be 'More Incremental,' RBC Says
- Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
- Raymond James reiterates Strong Buy on Climb Bio stock ahead of data
- Climb Bio to present Phase 2 data on kidney disease therapies
- Climb Bio to Present New Data at American Society of
Headlines from the last 30 days, linking to the original publishers. See all market news →